Gastroenterology: NTC submits marketing authorisation application for KLEERKOL® in EU
MILAN, April 19, 2022 /PRNewswire/ -- NTC Srl, R&D driven pharmaceutical company with headquarters in Italy announces the submission of the marketing authorisation application through the European Decentralised Procedure (DCP) for its development product NTC015 (Kleerkol®) for bowel preparation for colonoscopy. "Colonoscopy remains the standard for diagnosing and monitoring colorectal cancer and for diagnosis and surveillance of inflammatory...
Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19
- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3CLpro, with global intellectual property rights. - It is expected that IND of...
Paving the Last Mile, Fosun Foundation Delivers Essentials to Hundreds of Communities in Shanghai
HONG KONG, April 19, 2022 /PRNewswire/ -- Since the latest COVID-19 outbreak which started in March in Shanghai, China, Fosun Foundation has been promptly responding to the needs from the city's universities, hospitals, and communities. On April 1, Fosun Foundation initiated the "Community Support Action", and helped pave the last mile of logistics. As of April 18, over 670,000 pieces...
Mediscience Espoir Inc. Looking for OEM Customers, Technical Business Partners and Sales Agents for Oxygen Clathrate Hydrates and Oxygen Solutions
KAWASAKI, Japan, April 19, 2022 /PRNewswire/ -- Mediscience Espoir Inc. announced on April 19 that it is looking for U.S. partners for oxygen clathrate hydrates and oxygen solutions based on its proprietary technology. The company obtained "Substance Patent" in the United States (US 10,913,037 B2) in February 2021 for oxygen clathrate and oxygen solutions containing the same, with the patent used for producing...
Translumina launches VIVO ISAR, its Dual-Drug Polymer-free Coated Stent (DDCS) in International markets
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey NEW DELHI and HECHINGEN, Germany, April 19, 2022 /PRNewswire/ -- Translumina, a global developer and manufacturer of innovative cardiovascular medical devices used in interventional cardiology, announces the launch of VIVO ISAR, its latest generation dual drug polymer-free coated...
Pondok Indah Hospital Group first in Indonesia to achieve HIMSS EMRAM Stage 6
JAKARTA, Indonesia, April 19, 2022 /PRNewswire/ -- HIMSS announced today that Pondok Indah Hospital Group has become the first healthcare provider in Indonesia to achieve Stage 6 on the HIMSS Electronic Medical Record Adoption Model (EMRAM). The eight-stage EMRAM measures clinical outcomes, patient engagement and clinician use of electronic medical record technology to strengthen organisational performance and health outcomes...
GILEAD SCIENCES AND NATIONAL FOUNDATION OF DIGESTIVE DISEASES SET OUT TO STRENGTHEN LEARNING, ACCESS TO LIVER HEALTH EDUCATION IN SINGAPORE
-- Gilead Sciences supports National Foundation of Digestive Diseases with grant funding to improve liver health education in Singapore as part of its Asia Pacific ALL4LIVER Grant -- -- The National Foundation of Digestive Diseases gets digital upgrade to enhance liver health awareness and education -- -- General apathy among Singaporeans towards...
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day
NANJING, China, April 19, 2022 /PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China held its first R&D day for international investors, during which the executive leaders revealed Simere's R&D strategy, and gave an update on Simcere's pipeline to the global investment community. Mr. REN Jinsheng, Chairman and CEO, Dr. TANG...
MGI announces partnership with Nalagenetics to advance personalized medicine
The partnership will address some critical issues in pharmacogenetic assay through sequencing workflows improvement SINGAPORE, April 19, 2022 /PRNewswire/ -- MGI, a company committed to being a world-leading life science innovator, today announced a partnership with Nalagenetics (NALA) to co-develop low coverage whole genome sequencing for risk prediction and population genomics through optimizing Next Generation Sequencing (NGS)...
Bridge Biotherapeutics Enters into an Exclusive License Agreement with Shaperon to Strengthen Its IPF Franchise
The licensing deal includes an upfront payment of USD 1.63 million, and may reach up to USD 24.4 million in milestone payments and royalties By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF) SEONGNAM, South Korea, April 19, 2022...
